CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$43.14 USD
-0.40 (-0.92%)
Updated Mar 23, 2023 04:00 PM ET
After-Market: $43.17 +0.03 (0.07%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About EPS Diluted (TTM)
The company's trailing twelve month (TTM) EPS Diluted value tell you how the company has done in the past 12 months. Diluted earnings per share offer a worst-case scenario -- what the company's stock would look like if the company had to immediately issue every share it had promised in stock options or convertible bonds. A company's diluted earnings per share is calculated by dividing the company's annual profit by its number of outstanding shares. A company with $1 million in profit and 1 million shares of outstanding stock has an EPS of $1.
CRSP 43.14 -0.40(-0.92%)
Will CRSP be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
CRISPR Therapeutics AG (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Intellia's (NTLA) HAE Therapy Granted RMAT by the FDA
Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
Other News for CRSP
CRSP May 5th Options Begin Trading
FDA to back accelerated approval pathway for gene therapies
Crispr Therapeutics initiated with a Market Perform at Bernstein
Crispr Therapeutics price target lowered to $55 from $63 at Citi
3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time